From Nasdaq: 2025-06-04 21:49:00

Akeso Inc. receives approval from NMPA for cadonilimab, a PD-1/CTLA-4 bispecific antibody, for first-line treatment of cervical cancer in combination with platinum-based chemotherapy. Cadonilimab now has three approved indications and is included in 16 clinical treatment guidelines for various cancers. It is also being studied in over 30 Phase II and III trials for different cancer types and stages. For more health news, visit rttnews.com. The views expressed in the article are those of the author and do not necessarily reflect those of Nasdaq, Inc.



Read more at Nasdaq: Akeso’s Cadonilimab Gets NMPA Approval For First-line Cervical Cancer Treatment